GoodRx Holdings, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 6, 2024, details the results of GoodRx Holdings, Inc.'s Annual Meeting of Stockholders. The meeting was held to vote on director elections, auditor ratification, and executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
Approximately 98.7% of the combined voting power of Class A and Class B common stock was present or represented by proxy. All three proposals were approved by stockholders:
- Director Elections: Douglas Hirsch, Kelly J. Kennedy, and Agnes Rey-Giraud were elected as Class I directors for a term expiring in 2027.
- Auditor Ratification: PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Executive Compensation: The compensation of named executive officers was approved on an advisory (non-binding) basis.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the reporting of the stockholder vote results.
Investor Verification Checklist
- Verify the final vote counts for the three Class I director nominees to confirm the margin of approval.
- Confirm the ratification of PricewaterhouseCoopers LLP as the auditor for the 2024 fiscal year.
- Review the Definitive Proxy Statement filed on April 25, 2024, for detailed descriptions of the proposals and executive compensation specifics.
- Note the dual-class voting structure where Class B shares held ten votes per share compared to one vote per Class A share.